NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages

NeuroPace, Inc. (NASDAQ:NPCE) has been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $18.8333.

A number of analysts have recently commented on NPCE shares. Wall Street Zen lowered shares of NeuroPace from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. HC Wainwright lifted their price target on shares of NeuroPace from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Wells Fargo & Company raised shares of NeuroPace to a “strong-buy” rating in a research report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, June 24th.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds and other institutional investors have recently bought and sold shares of NPCE. First Light Asset Management LLC grew its position in shares of NeuroPace by 82.3% in the first quarter. First Light Asset Management LLC now owns 2,459,966 shares of the company’s stock valued at $32,349,000 after purchasing an additional 1,110,484 shares during the last quarter. Vanguard Group Inc. lifted its holdings in NeuroPace by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 1,435,850 shares of the company’s stock worth $14,804,000 after purchasing an additional 66,574 shares during the last quarter. Armistice Capital LLC lifted its holdings in NeuroPace by 12.6% during the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock worth $13,382,000 after purchasing an additional 145,665 shares during the last quarter. Kotler Kevin bought a new stake in NeuroPace in the 4th quarter valued at $9,750,000. Finally, Geode Capital Management LLC boosted its stake in NeuroPace by 6.5% in the 4th quarter. Geode Capital Management LLC now owns 596,248 shares of the company’s stock valued at $9,208,000 after purchasing an additional 36,516 shares during the period. Institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Performance

Shares of NeuroPace stock opened at $16.97 on Friday. The company has a market capitalization of $578.51 million, a PE ratio of -26.11 and a beta of 1.88. NeuroPace has a 12 month low of $7.56 and a 12 month high of $19.60. The company has a current ratio of 5.38, a quick ratio of 4.35 and a debt-to-equity ratio of 4.08. The stock’s fifty day simple moving average is $16.33 and its 200 day simple moving average is $15.62.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.06. NeuroPace had a negative net margin of 21.67% and a negative return on equity of 108.20%. The firm had revenue of $22.00 million for the quarter, compared to the consensus estimate of $21.65 million. On average, research analysts predict that NeuroPace will post -0.54 EPS for the current year.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.